Literature DB >> 32235911

No anti-fibrotic effect of selonsertib in NASH.

Iain Dickson1.   

Abstract

Entities:  

Year:  2020        PMID： 32235911     DOI： 10.1038/s41575-020-0297-5

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.

Authors:  Stephen A Harrison; Vincent Wai-Sun Wong; Takeshi Okanoue; Natalie Bzowej; Raj Vuppalanchi; Ziad Younes; Anita Kohli; Shiv Sarin; Stephen H Caldwell; Naim Alkhouri; Mitchell L Shiffman; Marianne Camargo; Georgia Li; Kathryn Kersey; Catherine Jia; Yanni Zhu; C Stephen Djedjos; G Mani Subramanian; Robert P Myers; Nadege Gunn; Aasim Sheikh; Quentin M Anstee; Manuel Romero-Gomez; Michael Trauner; Zachary Goodman; Eric J Lawitz; Zobair Younossi
Journal:  J Hepatol       Date:  2020-03-06       Impact factor: 25.083
  1 in total
  4 in total

1.  Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing.

Authors:  Mohammad Hassan Baig; Mohd Yousuf; Mohd Imran Khan; Imran Khan; Irfan Ahmad; Mohammad Y Alshahrani; Md Imtaiyaz Hassan; Jae-June Dong
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 3.  FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.

Authors:  Emma Henriksson; Birgitte Andersen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-22       Impact factor: 5.555

Review 4.  Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

Authors:  Madhangi Parameswaran; Hamzah A Hasan; Jafor Sadeque; Sharan Jhaveri; Chaithanya Avanthika; Abimbola E Arisoyin; Maulik B Dhanani; Swaroopa M Rath
Journal:  Cureus       Date:  2021-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.